Cytokines play an important role in the developmental programs of normal hematopoiesis and leukemia. Signaling through cytokines receptors is mediated in part by the activation of tyrosine kinases, particularly the Janus kinases (Jaks). Many of the effects of Jak2 are mediated through the recruitment of signal transducer and activator of transcription (Stat) to phosphotyrosyl residues on the erythropoietin, granulocyte macrophage colonystimulating factor, and interleukin-3 receptors. Shp2, the nonreceptor tyrosine phosphatase encoded by PTPN11, also participates in signaling events downstream of the receptors of growth factors, cytokines, hormones, antigens, and extracellular matrixes. It has compound functions and is involved in a variety of signal transduction processes, such as the Ras-Raf-Map kinase, Jak-Stat, PI3 kinase, and nuclear factor-kB (NF-kB) pathways. Jak2 and Shp2 form a complex signaling network in hematopoietic progenitor cells. Perturbed Jak2 and Shp2 signalings may induce hematopoietic malignancies. Recently, a somatic point mutation of JAK2 (V617F), which results in constitutive activation of the tyrosine kinase and factor independent growth of hematopoietic cells, has been found in patients with myeloproliferative disorders.
1 Dominant mutations in PTPN11, which result in gain of function of shp2, have also been demonstrated in juvenile myelomonocytic leukemia (JMML). 2 Myelodysplastic syndrome (MDS) is a clonal disease usually characterized by hypercellular marrow with features of ineffective and dysplastic hematopoiesis, which can lead to fatal cytopenia or leukemic transformation. The mechanisms underlying the development of MDS and its progression to acute leukemia remain unclear. Activating mutations in N-RAS and K-RAS, which upregulate downstream signaling pathways, are frequently observed in MDS, and have been implicated in poor prognosis and increased risk of leukemia. 3 Studies on the genetic mutations of JAK2 and PTPN11 in MDS remain limited and there has been no report of simultaneous sequential study of both genes during clinical follow-up. In this study, we analyzed the mutations of JAK2, PTPN11, and RAS in patients with primary MDS and patients with JMML. Serial studies were performed during the follow-up period to assess the acquisition of mutations during disease progression.
One hundred and forty unselected patients with primary MDS diagnosed according to French-American-British (FAB) criteria at National Taiwan University Hospital were recruited. Ten patients were children (o18 years) and 130 were adults. Patients with antecedent hematological disease or therapyrelated MDS were excluded. Forty-two patients with MDS had serial studies during the clinical follow-ups. Ten patients with JMML were also recruited for comparison. Mutation of JAK V617F was detected by mutation specific polymerase chain reaction (PCR) and direct sequencing.
1 PTPN11 mutations were detected by PCR and direct sequencing using the primer sets covering exon 3 and exon 13. 2 The clinical characteristics and laboratory data of the patients are summarized in Table 1 . The median age was 63 years (range 1B88). Acute leukemic transformation occurred in 37 patients (26%; 5% in Refractory Anemia (RA)/RA with ringed sideroblasts (RARS), 38% in RA with excess of blasts (RAEB)/RAEB in transformation (RAEB-T) and 26% in chronic myelomonocytic leukemia (CMMoL)).
At diagnosis, two (1 RAEB-T, 1 CMMoL) of the 140 MDS patients were found to have JAK2 V617F mutations. Serial gene mutation studies were performed in 42 patients with a median follow-up time of 14 months (range 2-114 months). The gene mutation results of those patients with sequential changes are shown in Table 2 . Two of the 41 patients who did not show JAK2 mutation at diagnosis acquired mutation in this gene during disease progression (Table 2, Figure 1 ). In one patient who had JAK2 mutation at diagnosis and had serial analysis, the mutation remained unchanged 9 months later.
Four patients (2 RAEB, 1 RAEB-T, and 1 CMMoL) had PTPN11 mutation at diagnosis, including three in exon 3 and one in exon 13. Two of these patients had sequential gene analyses, both of which revealed disappearance of the PTPN11 mutation after the allogeneic hematopoietic stem cell transplantation (Table 2, Figure 2 ). PTPN11 mutation was not detected during serial follow-ups in the remaining 40 patients without this gene mutation at diagnosis.
RAS mutations were found at diagnosis in 13 patients (9.3%), including three patients with RAEB, six with RAEB-T, and four with CMMoL. Five of these patients had serial studies during follow up. In one of these patients, the N-RAS codon 12 mutation detected at initial study disappeared and a K-RAS codon 12 mutation developed at acute transformation ( Figure 3 ). Analysis in the remaining four patients revealed no changes in the mutations during subsequent follow-ups. Three patients who did not show RAS mutation at diagnosis acquired mutations in this gene at acute transformation ( Table 2 ). The occurrence of JAK2, PTPN11, or RAS mutation was mutually exclusive.
Among the 10 patients with JMML, six patients had PTPN11 mutations. None of the patients had JAK2 or RAS mutation. PTPN11 mutation was detected at diagnosis in five patients, but was not detected in the remaining one patient until follow up study four months after diagnosis ( Table 2) .
The correlation of genetic mutations with clinical and laboratory characteristics is shown in Table 3 . The median platelet count in the four patients with JAK2 V617F mutations was significantly higher than in the other MDS patients (P ¼ 0.015). The MDS patients with PTPN11 mutations were younger than those without the mutation (P ¼ 0.005). There was a significant difference in the incidence of PTPN11 mutation between children and adults with MDS (2/10 or 20% vs 2/130 or 1.5%, P ¼ 0.026). All but one patient with JAK2, PTPN11, or RAS mutation had a high-risk subtype of MDS (Tables 1 and 3) . Only one patient with low-risk MDS had genetic mutation identified at acute transformation but not at diagnosis (Table 2) . This is the first study to demonstrate that JAK2 and PTPN11 mutations can be acquired during progression of MDS or JMML. In one patient (CCS in Table 2 ), the JAK2 mutation was first detected 50 months after the diagnosis of CMMoL, and the disease evolved to RAEB-T (blast420%) 6 months later. In another patient (CWC), the JAK2 mutation was acquired at the time of acute leukemic transformation. Though no patient with MDS acquired PTPN11 mutation during serial gene analyses, one patient with JMML was found to have this mutation 4 months after diagnosis, and this patient died of sepsis 3 months later. These results suggest that JAK2 and PTPN11 mutations may play a role in disease evolution in some patients with MDS and JMML.
Tartaglia et al. 2 reported that 10% of children with MDS showed PTPN11 mutations. By contrast, adults with CMMoL or other subtypes of MDS had a low incidence (0-1.3%) of PTPN11 mutation. [4] [5] This study of both adults and children found that MDS patients with PTPN11 mutation were significantly younger and that children had a higher incidence of PTPN11 mutation than adults (20 vs 1.5%). It is assumed that the genetic changes underlying MDS in children are different from those in adults. The JAK2 mutation was detected in 3-13% of CMMoL and 1.5-5% of other MDS subtypes in adults, 6 but no study of the gene mutation in children has been reported. In this study, no difference in the incidence of JAK2 mutation was found between children and adults with MDS. Cytogenetic data were available in 131 patients with MDS and 9 patients with JMML. c One RA and one CMMoL patients who did not show JAK2 mutation at diagnosis acquired the mutation during disease progression (as shown in Table 2 ). One JMML patient who did not show PTPN11 mutation at diagnosis acquired the mutation 4 months after diagnosis. e One RAEB and two CMMoL patients who did not show RAS mutation at diagnosis acquired the mutation at acute transformation. 
Abbreviations: +, with mutation; À without mutation; AML, acute myeloid leukemia; CR, complete remission; C/T, chemotherapy; HSCT, allogeneic hematopoietic stem cell transplantation. a Serial analyses of the mutations were performed in 42 MDS patients and three JMML patients with a median follow-up time of 14 months (range 2-114). Those patients who had no changes during sequential follow-up were not shown in this table.
b FAB subtype at the time of study. c Interval (month) between the previous study and this study. The patient had N-RAS codon 12 mutation (N12) at diagnosis, but this mutation disappeared at acute transformation and a K-ras codon 12 mutation (K12) emerged instead.
In this study, JAK2, PTPN11, or RAS mutation was identified in a total of 24 patients. All of them had a high-risk subtype of MDS with the exception of one RA patient who acquired the JAK2 mutation at acute transformation (Table 2 ). Similar findings have been reported previously. 7 The proteins encoded by these three genes are involved in signaling pathways associated with cell proliferation which may explain why their mutations are more frequently found in high-risk subtypes of MDS.
Activating RAS mutation is a pivotal molecular lesion that is implicated in the pathogenesis of AML and MDS. A number of genetic lesions found in myeloid malignancies result in hyperactive RAS. The mutual exclusivity of RAS and PTPN11 mutations widely seen in JMML as well as in ALL suggests that mutant Shp2 proteins deregulate malignant cell growth through activation of RAS. 8 Whether interaction occurs between JAK2 and RAS remains unclear. In this study, we found that JAK2, PTPN11, and RAS mutations were mutually exclusive in MDS. Yin et al. 9 demonstrated that shp2 is phosphorylated by JAK1 and JAK2, and phosphorylated shp2 is capable of binding to Grb2, an adaptor protein that bridges the association of the receptor tyrosine kinase with RAS. The finding that JAK2, PTPN11, and RAS mutations are mutually exclusive suggests Figure 1 Sequential changes of JAK2 gene in patient CCS (please refer to Table 3 Sequential changes of RAS gene in patient HL (please refer to Table 3 ). Direct sequencing showing GGT4GAT at NRAS condon12 and wild-type sequence of KRAS at diagnosis (upper); but NRAS mutation disappeared at acute transformation and GGT4GAT at KRAS condon12 emerged instead (middle and lower, 2nd and 3rd analysis, see Table 3 ). Arrows indicate the location of various mutations.
Letters to the Editor that mutation of JAK2 may activate RAS through phosphorylation of shp2. In conclusion, this is the first report to demonstrate that JAK2 and PTPN11 mutations can be acquired during disease progression. The mutations were associated with highrisk subtypes of MDS or low-risk disease in progression. These mutations may play a role in the pathogenesis of some high-risk MDS. Table 3 Comparison of the clinical characteristics of MDS patients with JAK2, PTPN11, or RAS mutation and those without JAK2 V617F mutation P-value PTPN11 mutation P-value RAS mutation P-value 
